Risk Factors Update Summary
- Accumulated deficit increased from $242 million to $332 million, impacting financial condition significantly.
- The number of full-time employees increased significantly from 46 to 66, indicating business growth.
- Cash, cash equivalents, and marketable securities decreased from approximately $283 million to $263 million.
- The percentage of outstanding voting stock owned by executive officers decreased from 30% to 26%.
- Development plans expanded to include TERN-501 for metabolic diseases, broadening product portfolio.
- The company expanded its privacy law discussion, with 14 states passing comprehensive privacy laws.
- The company's manufacturing operations in China are now conducted in a single location, reducing operational risk.
- The company's ability to operate efficiently in China may be hindered by proposed legislation.
- The company's stock price and trading volume could decline if securities or industry analysts do not publish favorable reports.
- The company's ability to meet clinical supply demand may be impaired due to disruptions in the supply chain.
Full Text Changes in Most Recent 10-K
Intended use: review the highlighted statements. These are additions to the risk factors disclosure in the most recent 10-K filing compared to the previous 10-K filing. Deleted and moved text is less important and is shown for context.
To view the full company filings, click on the following link to be taken to the SEC EDGAR database landing page for the company: https://www.sec.gov/edgar/browse/?CIK=1831363&owner=exclude
This content requires a 'Free' membership to view. Please create one here.
This content requires a 'Free' membership to view. Please create one here.